Frequently Asked Questions
The global HIV rapid test kits market was valued at USD 1.2 Billion in 2022.
The HIV rapid test kits market is expected to grow at a CAGR of 2.90% between 2023 and 2030, reaching USD 1.46 Billion in 2030.
In 2022, the lateral flow immunoassay sector held 78.25% of the market.
The urine segment contributes the rest to the demand for HIV rapid test kits.
The hospital segment is expected to post the highest CAGR during the forecast period.
North America has a 31.06% market share of the worldwide HIV rapid test kits market
The top players include OraSure Technologies, Inc, Atomo Diagnostics, Chembio Diagnostic Systems, Inc and Sedia Biosciences Corporation. Other major players include BioSURE United Kingdom Ltd., Abbott Laboratories, Guangzhou Wondfo Biotech Co., Ltd., CTK Biotech, Inc. And Merck KGaA.
Increasing Demand for Point-of-Care Testing and Government Initiatives to Improve Access to HIV Testing are the major market drivers.
Rapid Diagnostic Test False Positives and Negatives Imitated, as well as Rapid Diagnostic Test Accuracy, are the major market restraints.
Raising Awareness and Educating People, as well as Self-Testing Kits, are becoming more popular are the major opportunities in the HIV rapid test kits industry.